Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.42 |
| ▸ | LMNA | P02545 | 6/20 | 0.42 |
| ▸ | TP53 | P04637 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2335532 | 1.00 | MAPT (0.42) | MAPTLMNATP53KMT2AMEN1 | |
| SCHEMBL12448577 | 1.00 | MAPT (0.42) | MAPTLMNATP53KMT2AMEN1 | |
| SCHEMBL2333612 | 0.94 | MAPT (0.41) | MAPTLMNATP53KMT2AMEN1 | |
| SCHEMBL2333615 | 0.94 | MAPT (0.41) | MAPTLMNATP53KMT2AMEN1 | |
| SCHEMBL2337190 | 0.94 | MAPT (0.44) | MAPTLMNATP53KMT2AMEN1 | |
| SCHEMBL2337186 | 0.94 | MAPT (0.44) | MAPTLMNATP53KMT2AMEN1 | |
| SCHEMBL2334181 | 0.93 | MAPT (0.43) | MAPTLMNATP53KMT2AMEN1 | |
| SCHEMBL2334184 | 0.93 | MAPT (0.43) | MAPTLMNATP53KMT2AMEN1 | |
| SCHEMBL2336586 | 0.91 | MAPT (0.42) | MAPTLMNATP53KMT2AMEN1 | |
| SCHEMBL12448370 | 0.91 | MAPT (0.42) | MAPTLMNATP53KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465882-B1 | HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2011-08-24 | — | — | EP | claimed |
| US-6696473-B2 | THIAZOLIDINONE DERIVATIVES; MODULATING CHOLESTEROL METABOLISM | X-CEPTOR THERAPEUTICS, INC. | 2004-02-24 | — | — | US | claimed |
| US-20030212111-A1 | Heterocyclic modulators of nuclear receptors | AKARNA THERAPEUTICS, LTD. (GB) | 2003-11-13 | — | — | US | claimed |
| EP-1465882-B1 | HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2011-08-24 | — | — | EP | disclosed |
| US-7115640-B2 | Heterocyclic modulators of nuclear receptors | X-CEPTOR THERAPEUTICS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1465882-A4 | HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2005-04-06 | — | — | EP | disclosed |
| EP-1465882-A2 | HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X-Ceptor Therapeutics, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040180942-A1 | Heterocyclic modulators of nuclear receptors | X-CEPTOR THERAPEUTICS, INC. | 2004-09-16 | — | — | US | disclosed |
| US-6696473-B2 | THIAZOLIDINONE DERIVATIVES; MODULATING CHOLESTEROL METABOLISM | X-CEPTOR THERAPEUTICS, INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030212111-A1 | Heterocyclic modulators of nuclear receptors | AKARNA THERAPEUTICS, LTD. (GB) | 2003-11-13 | — | — | US | disclosed |
| WO-2003060078-A2 | HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180942-A1 | Heterocyclic modulators of nuclear receptors | NR1H2, NR1H3, NR1H4 | MAPT 4111/4885LMNA 2921/4885TP53 4307/4885 |
| US-20030212111-A1 | Heterocyclic modulators of nuclear receptors | NR1H2, NR1H3, NR1H4 | MAPT 4111/4885LMNA 2921/4885TP53 4307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.